Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol

• Verfasst von: Jieu, Beverly [VerfasserIn]
• Verfasst von: Sykorova, Eliska [VerfasserIn]
• Verfasst von: Rohleder, Cathrin [VerfasserIn]
• Verfasst von: Marcolini, Elisabeth [VerfasserIn]
• Verfasst von: Hoffmann, Anna E. [VerfasserIn]
• Verfasst von: Köthe, Dagmar [VerfasserIn]
• Verfasst von: Leweke, F. Markus [VerfasserIn]
• Verfasst von: Couttas, Timothy A. [VerfasserIn]
• Titel: Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol
• Verf.angabe: Beverly Jieu, Eliska B. Sykorova, Cathrin Rohleder, Elisabeth Marcolini, Anna E. Hoffmann, Dagmar Koethe, F. Markus Leweke, Timothy A. Couttas
• E-Jahr: 2024
• Jahr: September 2024
• Umfang: 14 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar: 4. Juni 2024, Artikelversion: 30. Juni 2024 ; Gesehen am 11.11.2024
• Titel Quelle: Enthalten in: Psychiatry research
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1979
• Jahr Quelle: 2024
• Band/Heft Quelle: 339(2024), Artikel-ID 116005, Seite 1-14
• ISSN Quelle: 1872-7123
• DOI: doi:10.1016/j.psychres.2024.116005
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biomarker panel
• Sach-SW: Human sera
• Sach-SW: LC-MS/MS
• Sach-SW: Lipid
• Sach-SW: Sphingolipid metabolism
• K10plus-PPN: 1908218126

Abstract

Randomized clinical trials substantiate cannabidiol (CBD) as a next-generation antipsychotic, effective in alleviating positive and negative symptoms associated with psychosis, while minimising the adverse effects seen with established treatments. Although the mechanisms remain debated, CBD is known to induce drug-responsive changes in lipid-based retrograde neurotransmitters. Lipid aberrations are also frequently observed with antipsychotics, which may contribute to their efficacy or increase the risk of undesirables, including metabolic dysfunction, obesity and dyslipidaemia. Our study investigated CBD's impact following lipid responses triggered by interaction with second-generation antipsychotics (SGA) in a randomized phase I safety study. Untargeted mass spectrometry assessed the lipidomic profiles of human sera, collected from 38 healthy volunteers. Serum samples were obtained prior to commencement of any medication (t = 0), 3 days after consecutive administration of one of the five, placebo-controlled, treatment arms designed to achieve steady-state concentrations of each SGA (amisulpride, 150 mg/day; quetiapine, 300 mg/day; olanzapine 10 mg/day; risperidone, 3 mg/day), and after six successive days of SGA treatment combined with CBD (800 mg/day). Receiver operating characteristics (ROC) refined 3712 features to a putative list of 15 lipids significantly altered (AUC > 0.7), classified into sphingolipids (53 %), glycerolipids (27 %) and glycerophospholipids (20 %). Targeted mass spectrometry confirmed reduced sphingomyelin and ceramide levels with antipsychotics, which mapped along their catabolic pathway and were restored by CBD. These sphingolipids inversely correlated with body weight after olanzapine, quetiapine, and risperidone treatment, where CBD appears to have arrested or attenuated these effects. Herein, we propose CBD may alleviate aberrant sphingolipid metabolism and that further investigation into sphingolipids as markers for monitoring side effects of SGAs and efficacy of CBD is warranted.